Advancements in cancer research have transformed treatment options, leaving the era of untreatable diseases behind. Decades of dedicated studies are now yielding innovative therapies, including recent breakthroughs for chronic lymphocytic leukemia (CLL).
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Netherlands, affecting the lymph nodes as a form of blood cancer. Approximately 600 people are diagnosed annually, primarily those over 60, though younger individuals can also be affected. Men are twice as likely to develop it than women. Often asymptomatic, CLL may go undetected for years.
CLL disrupts B lymphocytes—white blood cells in the lymph nodes—causing them to multiply uncontrollably. This leads to swollen lymph nodes, an enlarged spleen (resulting in abdominal swelling and reduced appetite), and accumulation in bone marrow and blood. Healthy cells are displaced, triggering symptoms like fatigue, paleness, shortness of breath, dizziness, and occasionally heart issues.
In early, asymptomatic cases discovered incidentally, active monitoring with regular check-ups is standard, delaying treatment until symptoms arise. When needed, chemotherapy combined with immunotherapy helps control the disease. Additional therapies are available both in the Netherlands and internationally. TheSocialMedwork provides legal, safe access to medications not yet approved locally.
Patients often seek global options for CLL management. Kinase inhibitor Calquence (acalabrutinib) serves as monotherapy post-prior treatments or combined with Gazyva/Gazyvaro (obinutuzumab) as first-line therapy. Imbruvica (ibrutinib) and Venclyxto/Venclexta (venetoclax) are also used after initial therapies in various countries. TheSocialMedwork assists in legally obtaining these unavailable medications, bringing effective care closer to patients.
This is a sponsored article.
